PDCD1 and cancer: Recently, it has been reported that the anti-cancer therapeutic efficacy of immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1), such as the human IgG4 monoclonal antibody Nivolumab, was affected by the composition of the resident gut microbiota [40].